Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-NAC02 total neoadjuvant therapy with chemoradiation followed by CapeOX for locally advanced rectal cancer
jRCTs011220019Active, not recruiting
- Sponsor
- Public Trust Surgery Research Fund
- Start
- Nov 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of capecitabine and oxaliplatin in rectal cancer, sponsored by Public Trust Surgery Research Fund. Primary endpoint: Complete response rate after neoadjuvant therapy. Started Nov 2022; status: active, not recruiting.
02
Drugs
capecitabineoxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on jRCTs011220019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs011220019.